How common is truly benign MS in a UK population? by Tallantyre, Emma et al.
1Tallantyre EC, et al. J Neurol Neurosurg Psychiatry 2018;0:1–7. doi:10.1136/jnnp-2018-318802
ReseaRch papeR
How common is truly benign MS in a UK population?
emma clare Tallantyre,1,2 paula c Major,2 Michael J atherton,2 W adam Davies,2 
Fady Joseph,3 Valentina Tomassini,1,2 Trevor p pickersgill,2 
Katharine elizabeth harding,1,2 Mark Douglas Willis,1,2 Mia Winter,4 
Neil p Robertson1,2
Multiple sclerosis
To cite: Tallantyre ec, Major 
pc, atherton MJ, et al. J 
Neurol Neurosurg Psychiatry 
epub ahead of print: [please 
include Day Month Year]. 
doi:10.1136/jnnp-2018-
318802
1Division of psychological 
Medicine and clinical 
Neurosciences, cardiff University 
school of Medicine, cardiff, UK
2helen Durham centre for 
Neuroinflammation, University 
hospital of Wales, cardiff, UK
3Department of Neurology, 
Royal Gwent hospital, Newport, 
UK
4Department of clinical 
Neuropsychology, University 
hospital of Wales, cardiff, UK
Correspondence to
Dr emma clare Tallantyre, 
Division of psychological 
Medicine and clinical 
Neurosciences, cardiff University 
school of Medicine, cardiff, UK;  
Tallantyreec@ cardiff. ac. uk
Received 11 May 2018
Revised 5 July 2018
accepted 22 July 2018
© author(s) (or their 
employer(s)) 2018. Re-use 
permitted under cc BY-Nc. No 
commercial re-use. see rights 
and permissions. published 
by BMJ.
AbsTrACT
Objectives The prevalence and definition of benign 
multiple sclerosis (BMs) remain controversial. Most 
definitions are based on the expanded Disability 
status scale (eDss), not encompassing the wider 
impact of disease. The explanation for favourable 
outcomes remains unclear. We aim to provide a detailed 
characterisation of patients with low eDss scores at long 
disease durations.
Methods We screened a population-based registry 
containing 3062 people with Ms to identify individuals 
with unlimited walking ability at disease durations >15 
years. a representative cohort underwent detailed clinical 
assessment and classified as having BMs according to 
eDss score <3, no significant fatigue, mood disturbance, 
cognitive impairment or disrupted employment, and had 
not received a disease-modifying therapy. We determined 
patient-reported perceptions of Ms status and made 
comparisons with eDss-based definitions.
results Of 1049 patients with disease duration of 
>15 years, 200 (19.1%) had most recent eDss score 
<4.0. Detailed contemporary clinical assessment of a 
representative sample of 60 of these patients revealed 
48 (80%) had an eDss score of <4.0, 35 (58%) 
<3.0 and 16 (27%) <2.0. Only nine (15%) fulfilled our 
criteria for BMs; impaired cognition (57%) and effects 
on employment (52%) the most common causes for 
exclusion. Meanwhile, 33/60 (69%) patients considered 
their disease benign. population frequency for BMs was 
estimated at 2.9% (95% cI 2.0 to 4.1).
Conclusions comprehensive assessment reveals a 
small minority of people with Ms who appear genuinely 
benign after 15 years. study of such individuals may 
uncover insights about disease pathogenesis. however, 
discrepancy between patient perception and clinician 
perception of BMs undermines use of the term ’benign’ 
in clinical settings.
bACkgrOund
Long-term epidemiological studies have consis-
tently identified a modest proportion of patients 
for whom the impact of multiple sclerosis (MS) 
remains relatively small over many years, but the 
existence, population prevalence and patholog-
ical substrate of benign MS remain controversial.1 
The study of individuals with benign MS has the 
potential to uncover clues to mechanisms under-
lying favourable outcomes in MS, provide insights 
into new therapeutic targets and have implica-
tions for patient counselling, individual patient 
management and the construct of clinical trials. 
Estimates of the frequency of benign MS vary 
widely according to the definition used. One 
commonly cited definition has been an Expanded 
Disability Status Scale (EDSS) score of ≤3 at 10 
years from symptom onset, but around one quarter 
of patients meeting this definition accumulated 
further disability when followed up to 20 years.2–8 
Recent studies have suggested that a low EDSS 
status after 15 years of MS may be a more reliable 
marker of benign status.6 9
Defining benign MS solely based on EDSS is also 
likely to be flawed. The limitations of the EDSS 
have been well described,10 and include a heavy 
reliance on motor outcomes, and relative insensi-
tivity to fatigue and cognitive or mood disturbance. 
Clinician-derived measurements of ability may also 
fail to recognise impaired social functioning such as 
employment status, which can be a useful surrogate 
functional capacity reflecting quality of life in MS, 
even when controlling for physical ability.11
In this study, we explore the detailed phenotype 
of individuals with benign MS in a population-based 
cohort, according to a composite definition of 
minimal physical disability, no significant fatigue, 
mood disturbance, cognitive impairment or disrup-
tion to employment, in the absence of disease-mod-
ifying therapy (DMT), at least 15 years after 
symptom onset. We compare this rigorous clinical 
definition with patients’ own perception of their 
MS and use these data to estimate population prev-
alence for truly benign MS.
MeThOds
data collection
The neuroinflammatory service of the Univer-
sity Hospital of Wales is a tertiary referral service, 
supported by a network of community-based, 
nurse-led and primary care clinics. It serves the 
urban populations of Cardiff and Newport and 
surrounding areas of the South Wales valleys; a total 
population of 1.37 million.12Data on the prevalence 
of MS in this population were initially collected 
in a cross-sectional study, ascertaining cases from 
primary care, community, third sector and hospital 
records in 1985, 1988 and 2005.13–15Clinical data 
have been collected longitudinally in a systematic 
manner since 2002. Patients are seen by a specialist 
neurologist at first referral, followed up every 12 
months where possible and sent an annual ques-
tionnaire.16At initial assessment, data are collected 
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on demographic features, details of presenting symptoms and 
results of investigations. At all subsequent appointments, data 
are collected on relapses, current symptoms, disease course, 
therapeutic interventions and effects. Level of disability is also 
collected and measured by the EDSS score.17When full neuro-
logical examination is not possible, EDSS score is recorded 
according to patient report of walking ability and need for assis-
tance, which has been shown to be highly valid for EDSS scores 
of 4 and above.16For the purposes of this study, any individual 
who lacked recent clinical data was contacted by postal ques-
tionnaire or telephone to determine relapse history and current 
walking ability. Data were censored on 1 January 2017.
Clinical data are stored on a secure National Health Service 
database.
Participants
The cohort was initially screened for individuals with MS who 
were recorded as having preserved ability to walk (EDSS score 
<4) at last clinical encounter and at least 15 years after symptom 
onset. Any EDSS data recorded during relapse were excluded. 
The criteria of EDSS score <4 was used for screening as data are 
reliably recorded at every patient contact, whereas lower EDSS 
scores are only assigned when a patient is seen in person by a 
clinician. Individuals who had received DMT at any time were 
also excluded, to allow us to identify individuals with a benign 
rather than treatment-modified disease profile. All of the 200 
individuals who satisfied our screening criteria, except for 10 
who had previously expressed a preference not to be contacted 
for research purposes, were considered for inclusion. The first 
60 individuals to respond were invited to attend for a detailed 
clinical assessment. Groups assessed in person and not assessed 
in person were compared for any significant differences in age, 
sex, disease duration or last recorded EDSS score.
Clinical assessment
A structured interview was used to document relapse history, 
comorbid medical and psychiatric diagnoses, marital status, 
childbearing status and employment history. Socioeconomic 
status was derived from the patient’s current address using the 
Welsh Index of Multiple Deprivation (WIMD).18 Review of 
the medical records was used to confirm the diagnosis of MS 
according to contemporary internationally accepted diagnostic 
criteria.19 Neurological examination was used to measure EDSS 
score according to Neurostatus scoring.20 The Fatigue Assess-
ment Instrument (FAI) was used to quantify fatigue.21 The Beck 
Depression Index (BDI)22 was used to measure symptoms of 
depression. The overactive bladder symptom and health-related 
quality of life questionnaire (OABq)23 was used to detect symp-
toms of bladder overactivity. MS-impact scale 29 (MSIS-29)24 
was used to quantify the physical and psychological impact 
of disease. The nine-hole peg test (9-HPT) was used to assess 
arm function.25 Timed 25-foot walk, 9-HPT and Paced Audi-
tory Serial Addition Test (PASAT) were used to derive the MS 
functional composite using normative data from the National 
MS Society (NMSS) Task Force database according to published 
protocol.26
In order to gauge cognitive status, a battery of tests sampling 
the following areas was administered: perception (Visual Object 
and Space Perception Battery subtests 1–3 and 5–7; Birmingham 
Object Recognition Battery Overlapping Figures and Object 
Decision), estimated level of ability (Test of Premorbid Function-
ing-UK; WAIS IV Similarities and Matrix Reasoning), working 
memory (Wechsler Adult Intelligence Scale (WAIS) IV Digit 
Span and Letter–Number Sequencing), learning and memory 
(Brain Injury Rehabillitation Trust (BIRT) Memory and Informa-
tion Processing Battery (BMIPB)), information processing effi-
cacy (PASAT; BMIPB), psychomotor speed (WAIS IV Coding), 
executive function (Delis-Kaplan Executive Function System 
Verbal Fluency and Color–Word Interference), language (Verbal 
Naming Test27; Boston Naming Test; Wide Range Achievement 
Test 4 (WRAT4) Spelling) and calculation (WRAT4 Maths). A 
brief praxis screen was administered to gauge ideomotor and 
ideational apraxia.
Participants were also asked to report their own perception 
of their MS status (benign or non-benign) according to the 
following lay definition: “When referring to illness, ‘benign’ 
usually means a condition which has little or no harmful effects 
on a person. There are no complications and there is a good 
outcome or prognosis”.
Analysis
Employment was said to have been affected by MS when an 
individual retired early on ill-health grounds, worked less-
than-full-time hours or changed employment as a direct result 
of MS. Instances where individuals chose to retire or work 
less than full time for other reasons were excluded. Clinically 
significant fatigue was defined as a FAI severity subscore >4, 
according to previously validated methodology.21 A BDI score 
>14 was used to indicate the presence of depressive features in 
keeping with accepted practice.28 The OABq symptom-bother 
and health-related quality of life (HRQOL) subscores were 
transformed into a 0–100 scale.23 Higher transformed scores on 
the symptom bother scale are indicative of increasing symptom 
bother while higher scores on the HRQOL scale indicate better 
HRQOL. Data from a large sample of population controls, who 
had similar demographic features to our cohort (n=1434, mean 
age 54 years, 65% women), were used to calculate Z-scores for 
symptom-severity and quality-of-life scores. Either of an OABq 
symptom bother Z-score >1.6 or an OABq HRQOL Z-score 
<−1.6 was taken to indicate significant bladder overactivity. 
Cognitive test scores were converted to standard scores and 
age-corrected where possible with the exception of the PASAT, 
which was corrected for years in education as it is suggested that 
maths ability influences scores to a greater effect than age.29 
Cognitive impairment was defined as two or more scores at or 
below the 5% percentile when compared with normative data.
There is currently no agreed EDSS cut-off for the definition 
of benign MS. We chose to describe the characteristics of partici-
pants with EDSS scores <2, 3 and <4. Clinical and demographic 
variables were compared for each EDSS cut-off with respect to 
their more disabled counterparts using t-tests and the Mann-
Whitney U statistic where parametric assumptions were violated. 
The χ2 statistic (with Yates continuity correction) was used to 
examine associations in classifications in the group analyses 
for self-reported benign/not benign status. Additionally, Spear-
man’s correlation was used to examine the association between 
self-reported benign status and EDSS. Level of significance 
was considered to be p ≤0.01 owing to multiple comparisons. 
Cohen’s kappa statistic was used to measure agreement between 
patient-derived and clinician-derived measures of benign MS 
status.
The following definition for truly benign MS was used:Dura-
tion of at least 15 years from symptom onset.
 ► EDSS score <3.
 ► Has never received disease-modifying drugs.
 ► No significant impact of MS on employment.
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Figure 1 Flow chart illustrating cohort screening and selection. DD, 
disease duration; DMT, disease-modifying therapy; eDss, expanded 
Disability status scale; Ms, multiple sclerosis.
Table 1 Characteristics of participants according to EDSS
 edss
score <4
edss
score <3
edss
score <2
No of participants 48 35 16
Age, years 58 (9.4) 57 (9.3) 55 (9.9)
Sex, n (%) female 36 (75%) 28 (80%) 13 (81%)
Disease duration, years 28 28 28
Social deprivation (WIMD rank) 1499 1490 1667
Years in education 15 15 15
Predicted IQ 108 107 109
Employment affected by MS (%) 25 (52%) 14 (40%) 5 (31%)
Marital divorce (%) 18 (38%) 12 (34%) 6 (38%)
Parented a child (%) 40 (83%) 27 (77%) 12 (75%)
BDI score 7.7 6.4* 5.1*
FAI severity score 3.2 2.8* 2.9
MSIS-29 score 45 40* 35*
OABq symptom bother standard score 23 20 12*
Number cognitively impaired (%) 27 (57%) 21 (60%) 7 (44%)
Self-reported benign 33 (69%) 28 (80%)* 15 (94%)*
Truly benign, n (%) 9 (19%) 9 (26%) 9 (56%)
BDI >13: clinically significant depression. FAI >4 indicates clinically significant 
fatigue. MSIS-29: normal range, 29–145; lower scores indicate less impact. OABq: 
higher symptom bother score indicates more symptom bother. WIMD: 1, most 
deprived; 1909, least deprived.
*Statistically significant difference compared with remainder of those assessed 
(p<0.01).
BDI, Beck Depression Index; EDSS, Expanded Disability Status Scale; FAI, Fatigue 
Assessment Instrument; MS, multiple sclerosis; MSIS-29, Multiple Sclerosis Impact 
Scale;OABq, Overactive Bladder Questionnaire;WIMD, Welsh Index of Mass 
Deprivation;9-HPT, nine-hole peg test.
 ► No clinically significant fatigue.
 ► No depressive symptoms (according to BDI).
 ► No cognitive impairment according to our criteria.
Bladder symptoms were not included in the definition as 
significant bladder dysfunction was expected to contribute to the 
EDSS score. Data on the prevalence of truly benign MS within 
the individuals assessed were used to estimate prevalence within 
the entire South East Wales MS population.
resulTs
Records from 3062 patients registered with the regional neuroin-
flammatory services since 1985 were examined. On the data 
censor date, 2526 patients fulfilled diagnostic criteria, had been 
reviewed by a study clinician, followed prospectively and had 
complete datasets from disease onset (figure 1). Of these cases, 
2025 were alive and resident in the catchment. A total of 1126 
had disease duration exceeding 15 years, of whom 1049 (93%) 
had relevant EDSS data. Forty-six individuals with EDSS score 
recorded as <4 after at least 15 years had previously received 
disease-modifying therapy (mean duration 3.2 years, SD 3.1). 
Overall, 200 individuals had an EDSS score <4 at most recent 
clinical encounter at least 15 years from disease onset and had 
not previously received a DMT. The mean interval between the 
most recent clinical encounter and the screening censor date 
was 5.0 years (SD 5.9). The 60 individuals assessed in person 
were 45 women and 15 men, mean age 57 years (range 39–78) 
and mean disease duration 28 years (range 15–49). There were 
no significant differences in age, sex, disease duration or last 
recorded EDSS in those 60 individuals assessed in person and 
the 140 individuals who did not attend for clinical assessment.
benign Ms according to edss milestones after 15 years
Although the clinical cohort was selected on the basis of unlim-
ited walking ability at their most recent clinical encounter, 12 
out of 60 had reached an EDSS score ≥4 by the time of clinical 
review. Of the remaining 48 individuals, 35 had an EDSS score 
<3 and 16 had an EDSS score <2. Demographic and clinical 
features according to EDSS cut-offs are shown in table 1. There 
were no significant differences in sociodemographic variables 
between those in the EDSS score <2 or EDSS score <3 group 
compared with their more disabled counterparts. Less social 
deprivation was observed in the group with EDSS score <2 
compared with those with higher EDSS, but this did not reach 
statistical significance at our cut-off (median WIMD rank 1667 
vs 1397; p=0.04). All groups had levels of social deprivation 
that were below the population average (table 1).
Employment
Employment had been affected by MS in 40% of those with 
EDSS score <3 and 31% of those with EDSS score <2 (table 1), 
most commonly by the need to retire early, followed by the need 
to work fewer hours. Anecdotally, 10 individuals also reported 
that MS had directly influenced their career choice, for example, 
they had chosen to follow careers that they perceived to be less 
stressful or more flexible. Two of these individuals had EDSS 
score <2 and employment had otherwise been unaffected by 
MS.
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Figure 2 a representation of the clinical cohort (n=60, selected 
based on disease duration >15 years and no history of DMT), according 
to whether an individual fulfilled (white) or failed to fulfil (black) each 
additional criterion for truly benign Ms. cognition: no cognitive impairment 
according to our criteria. employment: no significant impact of Ms on 
employment. eDss: eDss <3. Mood: no depressive symptoms (according 
to BDI). Fatigue: no clinically significant fatigue. eDss, expanded Disability 
status scale.
Depression and fatigue
The prevalence of depressive symptoms was 6% among those 
with EDSS score <2 and 17% in those with EDSS score <3 (all 
cases were of mild or moderate depression). Scores of depression 
using BDI were lower in those with EDSS <2 and EDSS <3 
compared with individuals who had higher disability (table 1). 
The rates of clinically significant fatigue were 19% for EDSS 
score <2 and 23% for EDSS score <3. Fatigue severity scores 
were also lower in those with EDSS <3 compared with more 
disabled counterparts (EDSS ≥3), whereas scores between EDSS 
<2 participants and their more disabled counterparts (EDSS 
≥2), did not reach statistical significance (p=0.02, table 1). The 
prevalence of clinically significant bladder symptoms was 6% 
among those with EDSS <2% and 26% for those with EDSS <3. 
Overactive bladder symptom scores were lower in those with 
EDSS <2 vs their more disabled counterparts (p<0.001).
Cognition
The groups with EDSS scores<2 and<3 were well educated 
(mean 15 years in education) and were estimated to be of 
average range ability (table 1). Of those with EDSS score <2, 
44% were deemed to have cognitive impairment; the same 
was true for 60% of those with EDSS score <3 (table 1). The 
cognitive domains that were found to be significantly weaker in 
those with EDSS score <3 versus normative controls were speed 
of processing (PASAT, p=0.007) and visual recall following 
distraction (p=0.003). The difference in visual learning was of 
borderline significance using our cut-off (p=0.011). Normative 
comparisons were not made for the EDSS score <2 group due 
to its small size.
Truly benign Ms
Overall, nine individuals were found to meet the criteria for truly 
benign MS (1M:8F). Mean age at symptom onset was 27 years 
(range 16–39), median EDSS score 1.5 (range 1–1.5) and mean 
disease duration 31 years (range 18–49). Two out of nine (22%) 
individuals reported comorbidity that interfered with normal 
activities (vs 9 out of 51 (18%) individuals who did not fulfil 
criteria for truly benign MS). Reasons for failing to fulfil the 
criteria of truly benign MS are given in figure 2. The nature of 
the first relapse was optic neuritis in two cases, pure sensory limb 
symptoms in two cases, pure motor limb symptoms in one case, 
brainstem syndrome in two cases and mixed motor and sensory 
symptoms in two cases. Eight cases experienced complete 
recovery from their first relapse, while one experienced residual 
disability. Eight out of nine patients tested had unpaired oligo-
clonal bands in their cerebrospinal fluid at presentation. The 
relapse frequency for these nine individuals is shown in figure 3.
estimated prevalence of truly benign Ms
The prevalence of truly benign MS within the cohort individuals 
assessed in person in was 15% (9 out of 60). Extrapolating this 
figure to the cohort of eligible individuals who satisfied screening 
criteria (n=200, figure 1) gives an estimate of 30 people with 
truly benign MS out of 1049 with sufficient disease duration 
(2.9%; 95% CI 2.0 to 4.1).
self-reported benign Ms
Thirty-nine out of 60 (65%) individuals who underwent assess-
ment reported their MS to be benign according to the lay defini-
tion provided (table 2). There were no significant differences in 
age, disease duration, years in education, estimated ability or in 
number of impaired cognitive scores between those who reported 
their MS was benign and those who reported their MS to be 
non-benign. However, self-reported benign MS was significantly 
associated with lower EDSS scores (p=0.001), fewer depressive 
symptoms (p=0.008), lower fatigue severity (p<0.0005) and 
lower reported MS impact (p<0.0005). Self-reported benign MS 
status showed poor agreement with our composite definition of 
benign MS status (Kappa 0.17, 95% CI 0.056 to 0.291), and 
only fair agreement with EDSS-based definitions of benign MS 
status (EDSS <3, Kappa 0.37, 95% CI 0.130 to 0.607; EDSS 
<2, Kappa 0.27, 95% CI 0.104 to 0.434).
disCussiOn
In this study of a population-based cohort of individuals with MS, 
using comprehensive clinical assessment, we identified a small 
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Figure 3 schematic diagram representing relapse history of 9 patients classified as having benign Ms.
Table 2 Characteristics of participants according to self-reported 
disease status (benign or not benign)
 
self-reported to be 
‘benign’ Ms
n=39
self-reported to be 
‘not benign’ Ms
n=21
Age (mean, years) 57 58
Sex 28 female (72%) 17 female (81%)
Disease duration (mean, years) 28 28
WIMD 1407 1194
No cognitively impaired 21 (54%) 12 (57%)
Employment affected by MS 16 (41%) 15 (71%)
Comorbidity affecting normal 
activities
7 (18%) 4 (19%)
FAI severity score 3 5*
OABq symptom bother standard 
score
19 40*
BDI score 7 16*
EDSS (median, range) 2.0 (1.0–6.0) 3.0 (1.5–6.0)*
Timed 25 foot walk (mean, s) 4.6 5.3
9-HPT dominant hand (mean, s) 21.1 22.7
MS functional composite 0.3 0.0
MSIS-29 42 69*
BDI >13: clinically significant depression. FAI >4 indicates clinically significant 
fatigue. MSIS-29: normal range, 29–145; lower scores indicate less impact. OABq: 
higher symptom bother score indicates more symptom bother; WIMD: 1, most 
deprived; 1909, least deprived.
*Statistically significant difference (p<0.01).
BDI, Beck Depression Index; EDSS, Expanded Disability Status Scale; FAI, Fatigue 
Assessment Instrument; MS, multiple sclerosis; MSIS-29, Multiple Sclerosis Impact 
Scale–29;OABq, Overactive Bladder Questionnaire;WIMD, Welsh Index of Mass 
Deprivation;9-HPT, nine-hole peg test.
proportion (estimated at 2.9%) for whom morbidity remains 
low at disease durations of more than 15 years. The EDSS-based 
definitions of benign MS significantly underestimated morbidity 
including fatigue, cognitive impairment and bladder symptoms. 
We also showed that agreement between patients and clinicians 
on benign MS status was lacking.
Reported rates of benign MS vary widely in the literature 
from 6% to 64%, depending on the definition used and popu-
lation studied.2 4 30 31 EDSS-based definitions are convenient to 
apply but can be relatively insensitive to morbidity. In our study, 
EDSS score <2 was associated with higher rates of employment, 
less morbidity and a more favourable patient perception of MS 
than EDSS score <3. We also found that all nine individuals 
who fulfilled the definition of truly benign MS had EDSS scores 
lower than 2 (even though we had set the cut-off at EDSS <3). 
However, even among those with EDSS score <2 at 15 years, we 
observed 44% with significant cognitive dysfunction and 19% 
with clinically significant fatigue.
Data derived from two Italian clinic-based cohorts highlighted 
the insensitivity of EDSS-based definitions of benign MS to 
cognitive impairment, depression and fatigue.32 However, clinic 
cohorts may not be representative of the wider population of 
patients with MS. In this study, we chose to explore benign MS 
in a population-based cohort, which should reduce ascertain-
ment bias towards more severe cases. Over half of the patients in 
the Italian cohort were receiving DMT.32 We chose not to study 
those who had received disease-modifying drugs, as it becomes 
impossible to decipher treatment effects from the natural history 
of the disease.
EDSS-based definitions also lack any measure of functional 
capacity. Of those with EDSS score <2 after 15 years, 31% 
reported that MS had negatively affected their ability to work. 
Previous studies have demonstrated high rates of early retirement 
from work in individuals with MS, and that many of those who 
remain in work require temporary absence, changes in working 
hours or changes in responsibilities.33–35 Fatigue, depression and 
cognitive impairment appear to contribute, independently from 
physical disability, to employment status.35 A high proportion 
of individuals with MS who are unemployed would prefer to be 
in work,36 and unemployment is known to be associated with 
lower quality of life.37 We chose to exclude reports that MS 
had adversely affected career choice on the grounds that this 
statement was rather subjective. However, it is worth noting 
that two out of the nine individuals who met our definition of 
truly benign MS made this assertion. This reminds us that the 
retrospective identification of benign MS serves no benefit in 
allowing people to plan their lives during the early stages of MS.
Patients’ own perception of their illness is relevant to the label 
of benign MS. In this study, the patient-reported rate of benign 
MS considerably exceeded and showed poor agreement with the 
rate of truly benign MS. There is no accepted definition to offer 
patients when exploring whether they feel their MS is benign; 
the definition we chose incorporates the fundamental princi-
ples of low impact on a person, absence of complications and 
a favourable outcome and is in line with definitions provided 
by third-party support groups.38 39 The factors underlying the 
discrepancy between clinician-reported and patient-reported 
disease status deserves further study. In our study, patients’ 
report of disease status did align with their reports of disease 
impact (MSIS-29) and to some extent with EDSS, but patients’ 
copyright.
 o
n
 5 N
ovem
ber 2018 by guest. Protected by
http://jnnp.bmj.com/
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2018-318802 on 3 September 2018. Downloaded from 
6 Tallantyre ec, et al. J Neurol Neurosurg Psychiatry 2018;0:1–7. doi:10.1136/jnnp-2018-318802
Multiple sclerosis
perception of their disease status appeared to be driven as much 
by mood, fatigue and bladder function as by physical ability.
Despite the pitfalls of defining benign MS, studying those 
people with extremely favourable long-term outcomes may 
nevertheless offer insights into MS pathogenesis. Those nine 
individuals with truly benign MS all remained in a relapsing–
remitting state after at mean disease duration of 31 years. 
However, only two out of nine showed disease arrest within the 
first decade; the remainder all continued to experience relapses 
well into their second or third decade of MS. Over the entire 
course of their illness, their relapse rates appear low, but several 
experienced annualised relapse rates in the first decade that 
would warrant DMT in a modern-day MS clinic. Future work 
using MRI may help to reveal the pathological substrate of the 
preserved ability, whether it be low lesion load, preserved brain 
volume or sparing of eloquent regions such as the spinal cord.
We recognise that this study has some limitations. This is not 
an incident cohort in the truest sense. However, detailed studies 
in 1985 and 2005 used a wide range of sources to identify all 
prevalent cases of MS, including those who had only one clinical 
attack.14 40 All cases identified since 2002 have had prospective 
data collection, although individuals with a clinically isolated 
syndrome (CIS) have not been serially imaged over the entire 
duration of the follow-up. We, therefore, accept that a small 
number of individuals with CIS may have achieved late radiolog-
ical evidence of dissemination in time in the absence of a second 
clinical attack after 15 years of follow-up.41 It is also possible that 
some individuals with mild attacks may not have sought medical 
attention, which may lead to underestimation of the prevalence 
of benign MS. The 60 participants who underwent detailed clin-
ical assessment did not differ significantly from the 140 indi-
viduals who did not, according to several domains known to 
influence outcome, but it remains possible that the groups may 
have differed according to an untested domain. When devel-
oping our definition of truly benign MS, we selected domains 
that are well recognised to be of relevance and importance to 
individuals with MS but recognise that weighting the relative 
importance of different domains is problematic. It is impossible 
to exclude an effect of comorbidity on generic symptoms such 
as depression or fatigue, although our data suggest that comor-
bidity is not the primary driver of fatigue or depression in this 
cohort.
In conclusion, after detailed clinical assessment, a small 
minority of people with MS appear genuinely unaffected by 
symptoms after 15 years. The study of the individuals with 
extremely favourable outcomes may uncover insights about 
disease pathogenesis or repair. However, the insensitivity of 
EDSS-based definitions of benign MS and the discrepancy 
between patient and clinician perception of benign MS under-
mine use of the term ‘benign’ in the clinical setting.
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